Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Solary E, Itzylson R. How I treat chronic myelomonocytic leukemia. Blood. 2017;130:126–36.

    Article  CAS  Google Scholar 

  2. Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, et al. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: a large population-based study. Cancer. 2017;123:3754–62.

    Article  Google Scholar 

  3. de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753–62.

    Article  Google Scholar 

  4. Such E, Germing U, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121:3005–15.

    Article  CAS  Google Scholar 

  5. Elena C, Galli A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408–17.

    Article  CAS  Google Scholar 

  6. Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2015;171:239–46.

    Article  Google Scholar 

  7. Liu H, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, et al. Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia. Biol Blood Marrow Transpl. 2017;23:767–75.

    Article  Google Scholar 

  8. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, Childs BH, Mackinnon S, Boulad F, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood. 1998;91:1083–90.

    Article  CAS  Google Scholar 

  9. Jakubowski AA, Small TN, Young JW, Kernan NA, Castro-Malaspina H, Hsu KC, et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood. 2007;110:4552–9.

    Article  CAS  Google Scholar 

  10. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA, et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transpl. 2008;14:458–68.

    Article  CAS  Google Scholar 

  11. Perales MA, Jenq R, Goldberg JD, Wilton AS, Lee SS, Castro-Malaspina HR, et al. Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. Bone Marrow Transplant. 2010;45:1408–16.

    Article  Google Scholar 

  12. Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, et al. Comparative outcomes of donor graft CD34+ selection and immunosuppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol. 2012;30:3194–201.

    Article  CAS  Google Scholar 

  13. Tamari R, Chung SS, Papadopoulos EB, Jakubowski AA, Hilden P, Devlin SM, et al. CD34-selected hematopoietic stem cell transplants conditioned with myeloablative regimens and antithymocyte globulin for advanced myelodysplastic syndrome: limited graft-versus-host disease without increased relapse. Biol Blood Marrow Transplant. 2015;21:2106–14.

    Article  Google Scholar 

  14. Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI, et al. Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Biol Blood Marrow Transplant. 2016;22:1037–42.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported in part by the NIH/NCI Cancer Center Support Grant P30 CA008748, the New York State Empire Clinical Research Investigator Program (ECRIP), the MDS Research Fund, the Phyllis Dunn Fund, and the Satlin Research Fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We also acknowledge all patients and their family who allowed us to participate in their care and to present the summary of their clinical disease course over the years at the Memorial Sloan Kettering Cancer Center. Editorial support in the preparation of this paper was provided by Hannah Rice, ELS.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Richard J. Lin.

Ethics declarations

Conflict of interest

Dr Giralt reports research funding from Amgen, Actinium, Celgene, Johnson & Johnson, Miltenyi Biotec, and Takeda and serves as a consultant for Amgen, Actinium, Celgene, Johnson & Johnson, Jazz Pharmaceuticals, Miltenyi Biotec, Takeda, Novartis, Kite Pharma, and Spectrum Pharmaceuticals. Dr Perales reports honoraria from Abbvie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, and Takeda. He serves on DSMBs for Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune. He has also received research support for clinical trials from Incyte and Miltenyi Biotec. All other authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, R.J., Sanchez, M., Abbi, K. et al. Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft. Bone Marrow Transplant 55, 1632–1634 (2020). https://doi.org/10.1038/s41409-019-0723-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0723-x

Search

Quick links